Earnings ·
Sight Sciences, Inc. reported second quarter 2026 financial results on August 5, 2026, announcing a 20% year-over-year…
SGHTSight Sciences, Inc.
Sight Sciences, Inc. reported second quarter 2026 financial results on August 5, 2026, announcing a 20% year-over-year revenue increase to $23.4 million. Interventional Glaucoma revenue grew 8% to $20.7 million, while Interventional Dry Eye revenue surged 704% to a record $2.7 million. The company raised its full-year 2026 revenue guidance to $88–$92 million and reduced adjusted operating expense guidance to $92–$94 million. Net loss improved 63% to $4.4 million, or $0.08 per share, compared to $11.9 million in the prior year period. Sight Sciences operates in the medical device industry, developing and commercializing interventional technologies for glaucoma and dry eye disease.